Last reviewed · How we verify
Energique, Inc. — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Dentastat | PLATINUM | marketed | Non-Standardized Food Allergenic Extract [EPC] | Immunology | ||
| Multi-Phenolic | PIPERINE | marketed | Vitamin C [EPC] | Metabolic | ||
| Multi-Phenolic | PYRROLE | marketed | Vitamin C [EPC] | Other |
Therapeutic area mix
- Immunology · 1
- Metabolic · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- · 2 shared drug classes
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class
- Glaukos · 1 shared drug class
- Exela Pharma · 1 shared drug class
- Faculdade de Medicina do ABC · 1 shared drug class
- Forces of Nature · 1 shared drug class
- Chi Mei Medical Hospital · 1 shared drug class
- ABBVIE · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Energique, Inc.:
- Energique, Inc. pipeline updates — RSS
- Energique, Inc. pipeline updates — Atom
- Energique, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Energique, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/energique-inc. Accessed 2026-05-16.